GSK plc
Informe acción BATS-CHIXE:GSKL
Capitalización de mercado: UK£55.6b
Salud financiera de hoja de balance de GSK
Salud financiera controles de criterios 3/6 GSK tiene un patrimonio de accionistas total de £13.5B y una deuda total de £16.1B, lo que sitúa su ratio deuda-patrimonio en 119.4%. Sus activos y pasivos totales son £58.0B y £44.6B respectivamente. El BAIT de GSK es de £6.9B, por lo que su ratio de cobertura de intereses es de 13.1. Tiene efectivo e inversiones a corto plazo que ascienden a £3.2B.
Información clave
119.4%
Ratio deuda-patrimonio
Ratio de cobertura de intereses 13.1x Efectivo UK£3.21b Patrimonio UK£13.45b Total pasivo UK£44.60b Activos totales UK£58.05b
Actualizaciones recientes sobre salud financiera
Mostrar todas las actualizaciones
GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk Oct 24
GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents Oct 16
GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2 Oct 14 Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine Oct 08 Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion Sep 24
GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell Sep 19
GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX Sep 18
GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme Sep 13
GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon Sep 12
GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial Sep 11
GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease Aug 29 GSK plc Announces Zantac (Ranitidine) Litigation Update GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227 Aug 20
Gsk plc Announces Zantac (Ranitidine) Litigation Update Aug 16
GSK plc Announces Zantac (Ranitidine) Litigation Update Aug 06
GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit Aug 02
GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024 Jul 31
GSK plc Announces Blenrep EMA Filing Acceptance Jul 22
GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season Jul 12
GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer Jun 18
GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy Jun 13
GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million. Jun 08 GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin Jun 05
GSK plc Provides Litigation Update May 25
An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion. May 18
GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon Gsk plc Announces Board Committee Changes May 09
First quarter dividend of UK£0.15 announced May 04
GSK plc to Report Q2, 2024 Results on Jul 31, 2024 May 03
First quarter 2024 earnings released: EPS: UK£0.26 (vs UK£0.37 in 1Q 2023) May 01 GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli Apr 24
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate Apr 16
GSK plc, Annual General Meeting, May 08, 2024 Mar 26 GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024 Mar 09
GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin) Mar 08
New minor risk - Earnings quality Mar 04 GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders. Feb 15
Upcoming dividend of UK£0.16 per share at 3.5% yield Feb 15
GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B Feb 14
Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over Feb 07 Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (£17.3B) de GSKL no cubren sus pasivos a corto plazo (£21.5B).
Pasivo a largo plazo: Los activos a corto plazo (£17.3B) de GSKL no cubren sus pasivos a largo plazo (£23.1B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de GSKL (95.5%) se considera alta .
Reducción de la deuda: El ratio deuda-patrimonio de GSKL ha pasado de 183% a 119.4% en los últimos 5 años.
Cobertura de la deuda: La deuda de GSKL está bien cubierta por el flujo de caja operativo (46.2%).
Cobertura de intereses: Los pagos de intereses de la deuda de GSKL están bien cubiertos por el BAIT (13.1x cobertura).
Descubre empresas con salud financiera Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}